Wall Street analysts expect Albany Molecular Research, Inc. (NASDAQ:AMRI) to report $171.94 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Albany Molecular Research’s earnings, with the highest sales estimate coming in at $175.66 million and the lowest estimate coming in at $168.21 million. Albany Molecular Research reported sales of $120.81 million in the same quarter last year, which indicates a positive year over year growth rate of 42.3%. The business is scheduled to report its next quarterly earnings results on Thursday, August 3rd.
On average, analysts expect that Albany Molecular Research will report full-year sales of $171.94 million for the current fiscal year, with estimates ranging from $720.10 million to $726.44 million. For the next fiscal year, analysts forecast that the business will post sales of $777.43 million per share, with estimates ranging from $771.60 million to $781.64 million. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Albany Molecular Research.
Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.01. Albany Molecular Research had a negative net margin of 11.26% and a positive return on equity of 11.97%. The firm had revenue of $163.80 million for the quarter, compared to analysts’ expectations of $161.43 million. During the same period in the previous year, the company posted $0.07 EPS. The company’s quarterly revenue was up 55.1% compared to the same quarter last year.
Several equities research analysts have weighed in on the stock. BidaskClub lowered shares of Albany Molecular Research from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. J P Morgan Chase & Co lowered shares of Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. William Blair lowered shares of Albany Molecular Research from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 6th. First Analysis lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday, June 12th. Finally, Morgan Stanley lowered shares of Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 target price on the stock. in a report on Thursday, May 11th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $18.00.
Several large investors have recently modified their holdings of the company. Municipal Employees Retirement System of Michigan increased its stake in shares of Albany Molecular Research by 5.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 5,260 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 290 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Albany Molecular Research during the first quarter valued at about $158,000. Sii Investments Inc. WI increased its stake in shares of Albany Molecular Research by 2.2% in the first quarter. Sii Investments Inc. WI now owns 11,460 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 250 shares in the last quarter. Arizona State Retirement System increased its stake in shares of Albany Molecular Research by 0.9% in the first quarter. Arizona State Retirement System now owns 11,586 shares of the biotechnology company’s stock valued at $163,000 after buying an additional 100 shares in the last quarter. Finally, Thrivent Financial For Lutherans increased its stake in shares of Albany Molecular Research by 5.4% in the first quarter. Thrivent Financial For Lutherans now owns 12,640 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 650 shares in the last quarter. 76.19% of the stock is owned by institutional investors.
Albany Molecular Research (AMRI) traded down 0.05% during trading on Thursday, reaching $21.72. 368,574 shares of the company’s stock traded hands. The company’s market cap is $903.64 million. The firm’s 50 day moving average is $21.68 and its 200 day moving average is $17.76. Albany Molecular Research has a 12 month low of $13.01 and a 12 month high of $22.17.
Albany Molecular Research Company Profile
Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.
Get a free copy of the Zacks research report on Albany Molecular Research (AMRI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
